Entecavir
- Generic Name
- Entecavir
- Brand Names
- Baraclude, Entecavir Viatris (previously Entecavir Mylan), Entecavir Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C12H15N5O3
- CAS Number
- 142217-69-4
- Unique Ingredient Identifier
- NNU2O4609D
- Background
Entecavir is an oral antiviral drug used in the treatment of hepatitis B infection. It is marketed under the trade name Baraclude (BMS).
...
- Indication
For the treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.
- Associated Conditions
- Chronic Hepatitis B Infection
- Associated Therapies
- -
Comparative Trial of Entecavir Versus Adefovir in the Treatment of Chronic Hepatitis B Infection
- First Posted Date
- 2004-11-16
- Last Posted Date
- 2010-08-10
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 69
- Registration Number
- NCT00096785
- Locations
- 🇹🇭
Local Institution, Bankok, Thailand
🇺🇸Local Insitution, New York, New York, United States
Entecavir for Subjects With Chronic Hepatitis B Infection: An Early Access Program
- Conditions
- First Posted Date
- 2004-11-16
- Last Posted Date
- 2016-09-21
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00096811
- Locations
- 🇮🇱
Local Institution, Zefat, Israel
Study of Adding Entecavir to Current Lamivudine Therapy in HIV and HBV Co-Infected Patients
- Conditions
- First Posted Date
- 2003-01-03
- Last Posted Date
- 2011-04-14
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00051038
- Locations
- 🇺🇸
Local Institution, Pittsburgh, Pennsylvania, United States
A Phase III Study of Entecavir vs Lamivudine in Chronic Hepatitis B Subjects With Incomplete Response to Lamivudine
- Conditions
- First Posted Date
- 2002-05-13
- Last Posted Date
- 2011-04-14
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00036608
- Locations
- 🇺🇸
Local investigator, Dallas, Texas, United States
🇺🇸Local Investigator, Richmond, Virginia, United States
A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Positive for Hepatitis B E Antigen
- Conditions
- First Posted Date
- 2002-05-06
- Last Posted Date
- 2011-04-14
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00035633
- Locations
- 🇺🇸
Local Investigator, Seattle, Washington, United States
🇺🇸Local Institution, San Francisco, California, United States
🇺🇸Investigator Meeting, Providence, Rhode Island, United States
A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Negative for Hepatitis B e Antigen
- Conditions
- First Posted Date
- 2002-05-06
- Last Posted Date
- 2011-04-14
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00035789
- Locations
- 🇺🇸
Local Investigator, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.